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Pathogenesis of eural Manifestations in Acute Porphyria
B.C.SHA LEY, V.A.PERCY, A.C. EEfHLING
SUMMARY
At least 4 possible mechanisms may be postulated to
explain the neural manifestations of acute porphyria in the
hereditary hepatic porphyrias. These are: (i) excessive
amounts of porphyrins or porphyrin precursors produced
in the liver during acute attacks are transported to the
central and peripheral nervous system, where they exert
neurotoxic effects; (ii) unidentified metabolites of the
aforementioned compounds may be responsible; (iii) in
patients with these diseases there may be a metabolic
defect in neural haem biosynthesis which is aggravated
by precipitating factors, thereby leading to acute neural
manifestations; and (iv) the hepatic and nervous system
lesions may be metabolically quite unrelated. Each of
these possibilities is considered, and evidence is adduced
that a genetic defect in haem biosynthesis in the nervous
system is the most plausible hypothesis.
S. Afr. med. J., 51, 458 (1977).
The hereditary hepatic porphyrias, viz. acute intermitteut
porphyria. variegate porphyria and hereditary copropor-
phyria. are well recognized as diseases in which there is
disordered liver haem bio ynthesis and a predisposition to
develop acute crises of a neurological or neuropsychiatric
nature, or both. These acute attacks can be life-threatening;
yet, unfortunately, virtually nothing is known of the under-
lying disturbance of neural function.
A number of hypotheses concerning the pathogenesis of
the acute neurobiological disturbances deserve considera-
tion. Firstly, porphyrins or porphyrin precursors which
are overproduced in the liver during acute attacks may
be transported to the central and peripheral nervous sys-
tems and may exert neurotoxic effects there. Alternately,
unidentified metabolites of the aforementioned compounds
may be responsible. Thirdly, there may be a metabolic
defect in neural haem biosynthesis which is aggravated
by precipitating factors, thereby leading to acute neural
manifestations. Fourthly, the hepatic and nervous system
lesions may be metabolically quite unrelated. These pos-
sibilities will be discussed, commencing with the least
probable and proceeding ultimately to show why a genetic
defect in neural cell haem bio ynthesis is the most plau-
ible theory.
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U RELATED HEPATIC AND NEURAL
LESIO S
This is patently the least attractive hypothesis, since it is
not readily testable, while the other 3 do afford oppor-
tunities for experimentation. Furthermore, the fact that
chemical compounds such as barbiturates, which are known
precipitating agents of the acute neurological disorder,
also affect hepatic haem biosynthesis, suggests some meta-
bolic Link between Iiv;:r and nervous system dysfunction
in this group of diseases.
PossmLE NEUROTOXICITY OF PORPHY·
RINS OR PORPHYRIN PRECURSORS
The simplest and most convenient explanation for the
neurological manifestations in acute porphyria is undoub-
tedly that one or more of the haem precursors which are
overproduced in the liver during acute crises, is neurotoxic.
This proposal was the first examined during the 1950s
by Goldberg and Rimington" and by Jarrett and co-
workers." Their studies appeared to exclude cS-aminolae-
vulinic acid (ALA), porphobilinogen (PBG) and porphy-
rins" as possible toxic agents.
Jnterest in this postulate has recently been revived, fol-
lowing the demonstration in vitro that: (t) ALA and PBG
can cause presynaptic inhibition of neurotransmitter re-
lease;'· (ii) ALA is an inhibitor of A+K+-dependent ATP-
ase in brain;' and (iii) ALA and PSG exert an inhibitory
effect on monosynaptic reflex activity in the isolated frog
spinal cord" and can decrease the resting membrane po-
tential of frog sartorius muscle.'
o studies to date have shown, however, that ALA
or PBG can penetrate the blood-brain barrier sufficiently
to achieve concentrations in brain tissue or in cerebro-
spinal fluid (CSF) which approximate those necessary to
cause the abovementioned inhibitory effects. Experiments
in our laboratory have clearly shown that, in adult and
wean ling rats, maximal brain concentrations of ALA and
PSG following intraperitoneal administration are approx-
imately 4 - 8~~ of maximal blood levels."""
These findings are consistent with the fact that no marked
behavioural, neurological or electro-encephalographic dis-
turbances have been noted following intraperitoneal in-
jection of ALA or PBG in rats and mice. lO,,..,. There are
few reports of porphyrin precursor concentrations in CSF
of patients with acute porphyric attacks. Available data
are summarized in Table 1. Tt is noteworthy that CSF
levels of porphyrin precursors during acute attacks have
been found to be much lower (0 - 22°~) than those in blood
sampled concurrently. The highest value recorded for ALA
in CSF i 280 /Lg/l 00 ml and for PSG it is 79 /Lg/lOO
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TABLE I. CONCENTRATIONS OF PORPHYRIN PRECURSORS IN BLOOD AND CSF OF PATIENTS WITH NEUROLOGICAL
AND/OR PSYCHIATRIC MANIFESTATIONS OF ACUTE PORPHYRIA
Blood CSF
ALA PBG ALA PBG
Authors Diagnosis (J.Lg/100 ml) (Vg/lOO ml) (J.Lg/100 ml) (J.Lg/100 ml)
Goldberg 12 AlP NO
Sweeney et ai"~ AlP 2 400 280 14
Bonkowsky et a/-' AlP 91 363 0 79
Bonkowsky et al.' AlP 38 393 5 50
Percy and Shanley" VP <50 <50 <25 <25
Percy and Shanley" VP 113 143 3,5 32
NO = not detectable; AlP = acute intermittent porphYria; VP = variegate porphyria.
ml. These CSF concentrations are below those required
to produce the inhibitory effects on neural tissue in
vitro.~,lO·I"
ALA and PBG, when introduced into the nervous sys-
tem in animals by intraventricular injection, are taken
up by brain tissue and are metabolized."''' There is no
evidence that porphyrin precursors, once having entered
neural tissue, accumulate there. Behavioural effects fol-
low intraventricular injection of 393 - 655 J.Lg ALA or
452 J.Lg PBG in adult rats.'" These effects are excitatory
~.nd transient in nature'" and cannot be equated with the
clinical manifestations of acute porphyria.
METABOLITES OF HAEM PRECURSORS
If haem precursors themselves are innocuous, could not
one or other of these compounds give rise to toxic
metabolites under conditions prevailing during acute at-
tacks of porphyria? It has been well shown that certain
compounds, such as fluroxene. which are otherwise inno-
cuous, give rise to highly toxic derivatives following meta-
bolism by hepatic microsomal cytochrome P-450.",16 Syn-
thesis of this microsomal enzyme in the liver is greatly
enhanced by many drugs, particularly those. such as bar-
biturates, which are known to play a role in the precipita-
tion of acute porphyria. Tt is just conceivable that induc-
tion of hepatic microsomal cytochrome P-450 in patients
with the hereditary hepatic porphyrias may lead to the
production of neurotoxic metabolites from ALA or PBG.
However, recent studies in our laboratory'" in which
young adult rats were treated with two intraperitoneal in-
jections per day of ALA (250 mg/kg) with or without
phenobarbitone (50 mgj kg) over a period of 3 days, re-
vealed no observable behavioural effects other than those
attributable to phenobarbitone alone.
DEFECT IN NEURAL HAEM BIOSYNTHESIS
The porphyrias have long been considered to be divisible
into two major groups, viz. the erythropoietic and the
hepatic porphyrias, according to the site of disordered
haem biosynthesis. It is now realized that this classification
is inadequate. Erythropoietic protoporphyria, for example,
is currently looked upon as an erythrohepatic disease as
opposed to a purely erythropoietic disorder. Similarly, it
7
has been found that patients with acute intermittent por-
phyria have decreased levels of uroporphyrinogen I (U R0
I) synthetase, not only in hepatocytes" but also in erythro-
cytes" and fibroblasts.' It is therefore quite likely that a
deficiency of this enzyme exists in other tissues, including
the cells of the central and peripheral nervou y terns in
patients with acute intermittent porphyria. 0 definitive
enzymatic deficiency in the haem biosynthetic pathway
has yet been described in the other two hereditary hepatic
porphyrias. But it is quite reasonable to expect that such
a defect does underlie the marked increase in haem pre-
cursor excretion accompanying acute attacks. If this is so_
then it is also reasonable to suggest that the postulated
enzymatic deficiency is common to the cells of the liver,
nervous system and probably other tissues of the body.
The available evidence strongly suggests that a profound
disturbance of neuronal or glial metabolism, or of both.
underlies the observed pathological lesions. Some authors
have described patchy but widespread demyelination af-
fecting predominantly peripheral nerves but also involving
the central nervous system.,,1l They regard the observed
axonal degeneration as secondary to loss of the myelin
sheath. Other studies have shown axonal degeneration to
be the main histological feature."" Either pathological
picture would be compatible with the hypothesis outlined
above, depending on whether neurons or glial cells were
most affected by the relative block in haem biosynthesis.
It is particularly interesting that asymptomatic patients with
acute intermittent porphyria and variegate porphyria, some
of whom have never experienced an acute attack, demon-
strate electromyographic evidence of peripheral neuro-
pathy." In other words, there is a latent genetic defect
present in the cells of the nervous system which may be
'activated' by a precipitating agent or circumstance.
Table Ir shows the results of preliminary studies on
haem biosynthesis in mammalian brain. Animals were
fasted 48 hours prior to administration of phenobarbitone
(100 mg/kg), allylisopropylacetamide (AlA) (400 mg/kg)
or phenobarbitone 50 mgjkg plus AlA (400 mg/kg) by
intraperitoneal route and sacrificed 18 hours later. Brains
were perfused with cold saline in situ prior to removal.
As might be expected, the values for ALA synthetase and
total haem are considerably lower than the corresponding
results for liver.~l M ore important, perhaps, is the apparent
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TABLE 11. EFFECT OF PHENOBARBITONE AND ALLYISOPROPYLACETAMIDE ON BRAIN HAEM BIOSYNTHESIS IN
YOUNG ADULT WISTAR RATS
Treatment
ALA synthetase (nmol/g/h)
Total haem (nmol/g wet wt)
















lack of any significant effect of phenobarbitone or AIA
treatment, alone or combined, on brain haem biosynthesis.
Thi sugge t that neural tissue i unable to alter its rate
of haemoprotein production according to demand.
In the case where one of the enzymes other than ALA
synthetase becomes rate-limiting, e.g. URO I synthetase
as postulated for acute intermittent porphyria, a state of
relative haem deficiency may ensue in the cells of the ner-
vous system. The condition would, however, remain asymp-
tomatic until one or other precipitating agent or factor
further reduced haemoprotein function and seriously in-
terfered with intracellular energy transfer, thereby dis-
rupting normal neural activity and leading, if prolonged,
to cell degeneration and necrosis. In this connection
barbiturates and certain steroids are well known for
their inhibitory effect on mitochondrial electron trans-
port through inhibition of ADH oxidase.···
Recently, haematin infusions have been employed the-
rapeutically in a number of patients with acute porphyria,
apparently to good effect.3.'.'4." Watson and co-workers"
have attempted to explain their results in terms of feed-
back repression of hepatic ALA synthetase with con-
sequent decreased production of ALA and PBG. While
the haematin infusions may well be exerting such an ef-
fect on the liver, this is unconvincing as an explanation for
amelioration of the neural signs and symptoms, for the
reasons already given. If the administered haematin is
taken up by cells it would seem more reasonable to postu-
late that it may well be compensating for deficient endo-
genous production of haem in neurons or glia, or in both,
thereby restoring haemoprotein concentrations and func-
tions toward normal.
Further studies based on this hypothesis promise to be
most rewarding in assisting to unravel the mysteries of the
acute attack in the hereditary hepatic porphyrias.
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